systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075082X.2020.2.200231systhiper-628Research ArticleОБЗОРREVIEWCOVID-19: пациент с сердечно-сосудистой патологией в зоне особого рискаCOVID-19: a patient with cardiovascular disease at high riskhttps://orcid.org/0000-0002-9822-4357ЧазоваИ. Е.ChazovaI. E.info@eco-vector.comЖернаковаЮ. В.ZhernakovaY. V.info@eco-vector.comhttps://orcid.org/0000-0002-0795-8225ОстроумоваО. Д.OstroumovaO. D.ostroumova.olga@mail.ruИнститут клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РоссииРоссияMyasnikov Institute of Clinical Cardiology, National Medical Research Center of CardiologyRussian FederationФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РоссииРоссияNational Medical Research Center of CardiologyRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation2020231220221727683Copyright © Чазова И.Е., Жернакова Ю.В., Остроумова О.Д., 20222022Чазова И.Е., Жернакова Ю.В., Остроумова О.Д.Chazova I.E., Zhernakova Y.V., Ostroumova O.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/628

Пандемия COVID-19, охватившая планету, поставила перед медиками всего мира множество вопросов, среди которых и тактика ведения пациентов с сердечно-сосудистой патологией, как инфицированных, так и находящихся в условиях самоизоляции. Данной проблеме был посвящен симпозиум, проведенный при поддержке компании «Мерк»: «COVID-19: пациент с сердечно-сосудистой патологией в зоне особого риска».

The COVID-19 pandemic that has swept the planet has posed many questions for doctors around the world, including the tactics of managing patients with cardiovascular disease, both infected and self-isolated. A symposium held with the support of the Merck company was devoted to this problem: "COVID-19: a patient with cardiovascular pathology at a particular risk".

ReferencesРоссийской медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020; 17 (1): 7-45Российской медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020; 17 (1): 7-45Bauters C, Lemesle G, Meurice T et al. Prognostic impact of b-blocker use in patients with stable coronary artery disease. Heart 2014; 100: 1757-61Bauters C, Lemesle G, Meurice T et al. Prognostic impact of b-blocker use in patients with stable coronary artery disease. Heart 2014; 100: 1757-61Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1)Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1)Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36 (10): 1953-2041. DOI: 10.1097/HJH.0000000000001940Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36 (10): 1953-2041. DOI: 10.1097/HJH.0000000000001940Struijker-Boudier H et al. The Need for Combination Antihypertensive Therapy to Reach Target Blood Pressures: What Has Been Learned From Clinical Practice and Morbidity-Mortality Trials? Int J Clin Pract 2007; 61: 1592-602Struijker-Boudier H et al. The Need for Combination Antihypertensive Therapy to Reach Target Blood Pressures: What Has Been Learned From Clinical Practice and Morbidity-Mortality Trials? Int J Clin Pract 2007; 61: 1592-602Cruckshank JM. Are We Misunderstanding Beta-Blockers. Int J Cardiol 2007; 120: 10-27Cruckshank JM. Are We Misunderstanding Beta-Blockers. Int J Cardiol 2007; 120: 10-27Palatini P et al. Impact of Increased Heart Rate on Clinical Outcomes in Hypertension: Implications for Antihypertensive Drug Therapy. Drugs 2006; 66: 133-44Palatini P et al. Impact of Increased Heart Rate on Clinical Outcomes in Hypertension: Implications for Antihypertensive Drug Therapy. Drugs 2006; 66: 133-44Murdoch D, Heel RC. Amlodipine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Cardiovascular Disease. Drugs 1991; 41 (3): 478-505. DOI: 10.2165/00003495-199141030-00009Murdoch D, Heel RC. Amlodipine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Cardiovascular Disease. Drugs 1991; 41 (3): 478-505. DOI: 10.2165/00003495-199141030-00009Rana R, Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. Indian Pract 2008; 61: 225-34Rana R, Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. Indian Pract 2008; 61: 225-34Parinello G, Paterna S, Torres D et al. One year Renal and Cardiac Effects of Bisoprolol versus Losartan in Recently Diagnosed Hypertensive Patients. Clin Drug Investigation 2009; 29: 591-600Parinello G, Paterna S, Torres D et al. One year Renal and Cardiac Effects of Bisoprolol versus Losartan in Recently Diagnosed Hypertensive Patients. Clin Drug Investigation 2009; 29: 591-600Klein LW, Richard AD, Holt J et al Effects of chronic tobacco smoking on the coronary circulation. J Am Coll Cardiol 1983; 1 (2 Pt 2); 421-6Klein LW, Richard AD, Holt J et al Effects of chronic tobacco smoking on the coronary circulation. J Am Coll Cardiol 1983; 1 (2 Pt 2); 421-6Cruickshank JM. The Modern Role of Beta-blockers in Cardiovascular Medicine. Shelton: CT Peoples Medical Publishing House-USA, 2011; Fig 3-32aCruickshank JM. The Modern Role of Beta-blockers in Cardiovascular Medicine. Shelton: CT Peoples Medical Publishing House-USA, 2011; Fig 3-32aBuhler FR, Berglund G, Anderson OK et al. Double-blind comparison of cardioselective B-blockers bisoprolol and atenolol in in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S 122-7Buhler FR, Berglund G, Anderson OK et al. Double-blind comparison of cardioselective B-blockers bisoprolol and atenolol in in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S 122-7

The authors declare that there are no conflicts of interest present.